Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06944717 · ClinicalTrials.gov registry record · Phase 1
A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old
A Phase 1 study of Norovirus Infections, sponsored by Vaxart.
- Active
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06944717 is a Phase 1 study of Norovirus Infections that is active but no longer recruiting, run by Vaxart. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06944717, a Phase 1 study of Norovirus Infections, is active but no longer recruiting, sponsored by Vaxart.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to determine the safety and immunogenicity of low and high dose regimens of a next generation norovirus bivalent G1.1 and G2.4 vaccine candidate in healthy participants.
Conditions Studied
Interventions
- BIOLOGICAL VXA-G1.1-NN
- BIOLOGICAL VXA-G2.4-NS
- BIOLOGICAL VXA G1.1 NN-T
- BIOLOGICAL VXA G2.4 NS-T
Study Locations (1)
Kansas
- Johnson County Clin Trials - JCCT - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06944717
The ClinicalTrials.gov registry entry for NCT06944717 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vaxart, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Norovirus Infections appearing as the primary indexed condition, and to 4 interventions - of which VXA-G1.1-NN is the first listed.
NCT06944717 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT06944717 about?
NCT06944717 is a clinical study titled "A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old". The primary objective of this study is to determine the safety and immunogenicity of low and high dose regimens of a next generation norovirus bivalent G1.1 and G2.4 vaccine candidate in healthy participants.
What is the current status of trial NCT06944717?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-03-03. Estimated completion is 2026-05-01.
What conditions does trial NCT06944717 study?
This clinical trial studies the following conditions: Norovirus Infections.
What interventions are being tested in trial NCT06944717?
The interventions under investigation include: VXA-G1.1-NN (BIOLOGICAL), VXA-G2.4-NS (BIOLOGICAL), VXA G1.1 NN-T (BIOLOGICAL), VXA G2.4 NS-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT06944717?
This trial is sponsored by Vaxart, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06944717 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.